These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
29. Therapeutic Suppression of Nonsense Mutation: An Emerging Target in Multiple Diseases and Thrombotic Disorders. Asiful Islam M; Alam F; Kamal MA; Gan SH; Wong KK; Sasongko TH Curr Pharm Des; 2017; 23(11):1598-1609. PubMed ID: 27875971 [TBL] [Abstract][Full Text] [Related]
30. Gentamicin treatment of Duchenne and Becker muscular dystrophy due to nonsense mutations. Wagner KR; Hamed S; Hadley DW; Gropman AL; Burstein AH; Escolar DM; Hoffman EP; Fischbeck KH Ann Neurol; 2001 Jun; 49(6):706-11. PubMed ID: 11409421 [TBL] [Abstract][Full Text] [Related]
31. Introducing sense into nonsense in treatments of human genetic diseases. Linde L; Kerem B Trends Genet; 2008 Nov; 24(11):552-63. PubMed ID: 18937996 [TBL] [Abstract][Full Text] [Related]
32. Sequence specificity of aminoglycoside-induced stop condon readthrough: potential implications for treatment of Duchenne muscular dystrophy. Howard MT; Shirts BH; Petros LM; Flanigan KM; Gesteland RF; Atkins JF Ann Neurol; 2000 Aug; 48(2):164-9. PubMed ID: 10939566 [TBL] [Abstract][Full Text] [Related]
33. Feasibility of nonsense mutation readthrough as a novel therapeutical approach in propionic acidemia. Sánchez-Alcudia R; Pérez B; Ugarte M; Desviat LR Hum Mutat; 2012 Jun; 33(6):973-80. PubMed ID: 22334403 [TBL] [Abstract][Full Text] [Related]
34. Gene selective suppression of nonsense termination using antisense agents. Kulyté A; Dryselius R; Karlsson J; Good L Biochim Biophys Acta; 2005 Sep; 1730(3):165-72. PubMed ID: 16135388 [TBL] [Abstract][Full Text] [Related]
35. Efficiency of translation termination in humans is highly dependent upon nucleotides in the neighbourhood of a (premature) termination codon. Pacho F; Zambruno G; Calabresi V; Kiritsi D; Schneider H J Med Genet; 2011 Sep; 48(9):640-4. PubMed ID: 21693480 [TBL] [Abstract][Full Text] [Related]
36. alpha-L-iduronidase premature stop codons and potential read-through in mucopolysaccharidosis type I patients. Hein LK; Bawden M; Muller VJ; Sillence D; Hopwood JJ; Brooks DA J Mol Biol; 2004 Apr; 338(3):453-62. PubMed ID: 15081804 [TBL] [Abstract][Full Text] [Related]
37. Aminoglycoside antibiotics: old drugs and new therapeutic approaches. Hermann T Cell Mol Life Sci; 2007 Jul; 64(14):1841-52. PubMed ID: 17447006 [TBL] [Abstract][Full Text] [Related]
38. Discovery of Clinically Approved Agents That Promote Suppression of Cystic Fibrosis Transmembrane Conductance Regulator Nonsense Mutations. Mutyam V; Du M; Xue X; Keeling KM; White EL; Bostwick JR; Rasmussen L; Liu B; Mazur M; Hong JS; Falk Libby E; Liang F; Shang H; Mense M; Suto MJ; Bedwell DM; Rowe SM Am J Respir Crit Care Med; 2016 Nov; 194(9):1092-1103. PubMed ID: 27104944 [TBL] [Abstract][Full Text] [Related]
39. Mechanism and evidence of nonsense suppression therapy for genetic eye disorders. Richardson R; Smart M; Tracey-White D; Webster AR; Moosajee M Exp Eye Res; 2017 Feb; 155():24-37. PubMed ID: 28065590 [TBL] [Abstract][Full Text] [Related]
40. The suppression of premature termination codons and the repair of splicing mutations in CFTR. Oren YS; Pranke IM; Kerem B; Sermet-Gaudelus I Curr Opin Pharmacol; 2017 Jun; 34():125-131. PubMed ID: 29128743 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]